Friday, June 19th 2020
10:00 AM - 11:30 AM
The Philadelphia Department of Health reports 23.8% of new HIV infections in 2018 were in persons assigned female sex at birth, higher than the national proportion of new infections in females(19%). Across both Philadelphia and the US, the majority of newly diagnosed females in 2018 identified as Black(58.4% and 59%, respectively) or Hispanic(21.7% and 16%, respectively). Despite these statistics, the CDC reports only 2.1% of eligible female patients received a prescription for HIV pre-exposure prophylaxis(PrEP) in 2016, with Black patients overall being 6 times less likely to be prescribed PrEP than white peers. To address this discordance between HIV risk and PrEP uptake, the present study examined the impact of a brief PrEP education session on female patients receiving family planning services at a Federally Qualified Health Center(FQHC) serving adolescents/young adults in Center City, Philadelphia.
Cisgender women ages 18-24 were prescreened using available electronic medical record data to confirm they were not already prescribed PrEP. Patients provided written informed consent prior to administration of pre-test/post-test surveys and PrEP education session. Knowledge of and attitudes toward PrEP(“PrEP acceptability”) were evaluated.
95 participants(age range:18-24 years) were 10.5% Hispanic/Latinx, 60% Black/African American, and 33.7% non-heterosexual(gay, bisexual, etc.). PrEP knowledge increased significantly after the education session(p<0.000), most notably regarding PrEP use outside of known HIV serodiscordance(p=0.003), the need for continued HIV testing on PrEP(p<0.000), and PrEP’s clinical indication for women(p<0.000). PrEP acceptability increased from pre to post-test(p=0.004). 15% of participants accepted a PrEP prescription following the education session.
Brief, structured PrEP education for cisgender women can have a significant impact on both knowledge and acceptability in the family planning setting.
Emily Hiserodt earned a Master of Public Health with a concentration in Health Policy and Management from Temple University in 2017. She has published multiple papers and presented research across several fields including HIV treatment and pre-exposure prophylaxis (PrEP), sexual and reproductive health, and behavioral economics. Currently, Emily is the Senior Research Coordinator for Philadelphia FIGHT Community Health Centers where she aids in conducting industry sponsored, CFAR, NIH/NIMH, and small grant funded work focusing on therapeutic drug monitoring for HIV negative patients taking PrEP, optimizing HIV treatment, HIV reservoir mapping and reversal, and ciswomen’s knowledge and attitudes toward PrEP.